Detalhe da pesquisa
1.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol
; 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889735
2.
Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis.
Eur Radiol
; 32(7): 4555-4564, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347362
3.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
4.
Improving the experience of older people with colorectal and breast cancer in patient-centred cancer care pathways using experience-based co-design.
Health Expect
; 24(2): 478-490, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33440059
5.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
6.
Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome.
Cytometry A
; 91(11): 1059-1067, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29024334
7.
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Haematologica
; 107(7): 1726-1730, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295081
8.
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica
; 106(8): 2257-2260, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657786
9.
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Haematologica
; 99(1): 148-54, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23996482
10.
Deferring diagnostic evaluation for suspected deep venous thrombosis using a single dose of anticoagulant: Real-world data from a regionwide care pathway.
Eur J Intern Med
; 122: 54-60, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151419
11.
Deferring diagnostic evaluation of suspected deep vein thrombosis using direct oral anticoagulant or low-molecular-weight heparin as a single dose anticoagulant: A prospective real-world study in a regionwide care pathway.
Thromb Res
; 240: 109059, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38850808
12.
Survey of Challenges, Goals, and Interventions for Patients With Lymphoma During Aftercare Consultation: An Exploratory Cross-Sectional Study.
J Patient Exp
; 10: 23743735231204470, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37811537
13.
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Blood
; 115(6): 1113-20, 2010 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-19880501
14.
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol
; 155(5): 599-606, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21981697
15.
Stories of Lymphoma Survivors in Early Aftercare: A Narrative Inquiry.
Cancer Nurs
; 44(6): 489-498, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604137
16.
CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) Trial: Long-Term Follow-Up Results.
J Am Heart Assoc
; 10(11): e018973, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34032127
17.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Lancet Haematol
; 7(12): e874-e883, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242444
18.
Association of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis with Postthrombotic Syndrome: A Post Hoc Analysis of the CAVA Trial.
Thromb Haemost
; 120(8): 1188-1199, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604427
19.
Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial.
Lancet Haematol
; 7(1): e40-e49, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786086
20.
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
J Clin Oncol
; 38(29): 3377-3387, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730183